NATURAL PRODUCT RESEARCH
5
3.3.1. (2R,4S,10S,12S)-2-[7-(12,13,16-trihydroxy-a-tetralonyl-13-O-b-D-glucopyrano-
side)]-4,8-dihydroxy-a-tetralone-4-O-b-D-glucopyranoside (1)
White amorphous power, [a]20 D -65 (c, 0.1, MeOH); HR-ESI-MS: m/z 735.1998
[M þ Na þ H2O]þ (calcd for C32H30O18Na 735.2003). 1H NMR (600 MHz, methanol-d4) d
7.55 (1H, d, J ¼ 9.1 Hz, H-14), 7.50 (1H, d, J ¼ 7.7 Hz, H-7), 7.31 (1H, d, J¼ 7.9 Hz, H-6), 7.12
(1H, d, J ¼ 7.7 Hz, H-5), 6.89 (1H, d, J ¼ 9.1 Hz, H-15), 5.44 (1H, d, J ¼ 3.2 Hz, H-4), 5.38 (1H,
d, J ¼ 3.2 Hz, H-12), 4.82 (1H, d, J ¼ 7.7 Hz, H-100), 4.62 (1H, d, J ¼ 7.7 Hz, H-10), 3.94 (1H, dd,
J ¼ 5.0, 1.6 Hz, H-600 ), 3.92 (1H, dd, J ¼ 5.0, 1.6 Hz, H-60a), 3.75 (1H, dd, J ¼ 5.0, 1.6 Hz, H-
a
600 ), 3.94 (1H, dd, J ¼ 5.0, 1.6 Hz, H-60b), 3.55 (1H, t, J ¼ 9.2 Hz, H-200), 3.40 (1H, m, H-30),
b
3.34 (1H, m, H-40), 3.33 (1H, m, H-50), 3.32 (1H, m, H-300), 3.31 (1H, m, H-400), 3.30 (1H, m,
H-500), 3.21 (1H, m, H-20), 3.15 (1H, m, H-2), 2.57 (1H, m, H-11a), 2.51 (1H, m, H-10), 3.24
(2H, m, H-3), 2.21 (1H, m, H-11b).13C NMR (101 MHz, Methanol-d4) d 206.4(C-9), 201.0(C-1),
159.0(C-16), 156.9(C-8), 148.8(C-13), 134.6(C-12a), 134.3(C-4a), 130.5(C-6), 129.6(C-8a),
128.4(C-14), 122.0(C-5), 119.0(C-15), 118.9(C-7), 116.1(C-16a), 104.5(C-100), 103.8(C-10),
78.3(C-300), 78.0(C-30/C-50), 77.9(C-500), 75.3(C-200), 75.2(C-20), 71.5(C-400), 71.2(C-40), 69.7(C-4),
62.6(C-600), 62.5(C-60), 61.2(C-12), 34.0(C-2), 33.6(C-10), 30.2(C-3), 30.0(C-11).
3.4. Acid hydrolysis of compound 1
Compound (4 mg) was treated with 1 M HCl (4 mL) at 90 ꢁC for 2 h. Then the reaction mix-
ture was extracted with CHCl3 (3 ꢂ 5 mL). The aqueous layer was collected and the water
was evaporated under vacuum with the repeated addition of MeOH to remove the solvent
completely. The residue was redissolved in anhydrous pyridine (2 mL) and mixed with a
pyridine solution of L-cysteine methyl ester hydrochloride (2 mL). After the mixed solution
was heated at 60 ꢁC for 1 h, trimethylchlorosilane (0.5 mL) was added and the resulting
mixture was stirred at 60 ꢁC for another 30 min. Then the solution was concentrated to
dryness and taken up in water (3ꢂ 1 mL), followed by extraction with n-hexane (3 ꢂ 1mL).
The supernatant was analyzed by GC. Separations were carried out on HP-5 columns
(320 mm ꢂ 30 cm, 0.25 mm). Highly pure N2 was employed as a carrier gas (1.0mL/min),
and the FID detector operated at 280 ꢁC (column temperature 160–200 ꢁC). The retention
times of the monosaccharide derivatives were as follows: and D-glucose (14.43 min).
3.5. Cytotoxicity
Human lung cancer cells (A549) and human cervical carcinoma cancer cells (HeLa) was pro-
vided by the American Type Culture Collection (ATCC). The cells were cultured in medium
(RPMI1640 for A549 and DMEM for HeLa) supplemented with 10% heat-inactivated fetal
bovine serum (FBS) and antibiotics antimycotics (PSF; 100 units/mL penicillin G sodium,
100 mg/mL streptomycin, and 250 ng/mL amphotericin B). The cells were incubated at 37 ꢁC
and 5% CO2 in a humidified atmosphere. Etoposide (Sigma, purity > 98%) was used as a
positive control. Cell viability was determined by the sulforhodamine B (SRB) protein staining
method. Cells were seeded in 96-well plates and incubated for 24 h, and were fixed (for zero
day controls) or treated with test compounds for 72 h. All compounds were solved in DMSO
(final concentration of 0.1%[v/v]), stored at ꢃ20 ꢁC and diluted to desired concentration
(0.01, 0.1, 1, 10, 100 lM) in normal saline immediately prior to each experiment. Each